2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3051

Bronchial Artery Enlargement May Cause Recurring Hemoptysis in Behçet’s Syndrome Patients with Pulmonary Artery Involvement Despite Response to Treatment
Abstract Number: 3052

Budd-Chiari Syndrome in Behçet’s Disease:a Retrospective Multicenter Study
Abstract Number: 3053

Patients Treated for Behcet Syndrome in the US Have Higher Disease Activity Scores at Presentation If They Fulfill ISG Criteria and If They Are Females, However Have Less Severe Disease Overall
Abstract Number: 3054

Takayasu’s Arteritis Associated with Behçet’s Syndrome: A Case Series of 8 Patients
Abstract Number: 3055

Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis
Abstract Number: 3056

Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis
Abstract Number: 3057

Can We Differentiate Takayasu’s Arteritis from Atherosclerosis Using Carotid Artery Doppler Usg?
Abstract Number: 3058

NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Abstract Number: 3059

Abnormal Body Composition in Takayasu Arteritis Patients: Role of Inflammatory Cytokines and Adipokines
Abstract Number: 3060

The Assessment of Disease Activity in Takayasu Arteritis; Six Years Experience from a Single Center
Abstract Number: 3061

Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study
Abstract Number: 3062

Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia
Abstract Number: 3063

Ocular Findings and Ocular Blood Flow Changes in Takayasu Arteritis: A Subclinical Reduction in Blood Flow with a Milder Clinical Course of Retinopathy
Abstract Number: 3064

Cardiac Manifestation of Takayasu Arteritis
Abstract Number: 3065

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Takayasu’s Arteritis in Large Healthcare Administrative Databases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].